News centre | United Kingdom

Philips Begins Clinical Trial Enrolment for Chill - MI Study

February 20, 2012

Lund, Sweden - Philips Healthcare recently announced the enrolment of the first patients in its CHILL-MI clinical study.   CHILL-MI is a prospective, randomised multi-centre study designed to further evaluate the safety and effectiveness of the company’s InnerCool RTx endovascular cooling system in patients suffering from ST-elevation myocardial infarction (STEMI).   The study will enrol 120 patients at multiple sites in Europe with a primary endpoint of reducing infarct size as a percentage of myocardium at risk, as assessed by cardiac MRI.   The study will also reinforce the safety and efficacy data demonstrated in the RAPID MI-ICE trial in a larger group.  The RAPID MI-ICE trial showed a 38 percent reduction in infarct size in STEMI patients who were cooled to a temperature of ‹35oC prior to performing angioplasty.

Following a myocardial infarction, restoring blood flow to the heart is critical to the survival of heart tissue.   However, this process may cause additional damage to the heart tissue.  Preventing tissue damage is arguably the most significant unmet medical need in the treatment of acute myocardial infarction and new standards of care are being investigated with the goal of improving patient outcomes.     According to researchers at Lund University in Sweden, one of the CHILL-MI study centres, the key to reducing infarct size is to cool patients with therapeutic hypothermia to ‹35oC prior to reperfusion or opening of the blocked artery.

“The success of the RAPID MI-ICE study was a breakthrough in the treatment of STEMI patients.  With the initiation of CHILL-MI, we aim to confirm the results in a larger multi-centre trial.  We hope this study will help to demonstrate the positive impact that therapeutic hypothermia can have on the outcomes of patients suffering acute MI and bring us a step closer to making it a standard of care.” says Dr. David Erlinge, Ph.D, head, department of cardiology at Lund University, Sweden and principal investigator for the CHILL-MI study.

The potential impact of improving treatment for STEMI is significant.  In the United States, the incidence of STEMI is approximately 77 per 100,000 individuals.  In Europe, this rate ranges from 44 to 142 individuals per 100,000, depending on the country, with Turkey having the highest and the UK having the lowest rates.

The Phase II/III CHILL-MI study will enrol 120 patients.   Patients in the treatment group will receive endovascular cooling therapy in combination with 1-2 L of cold saline.  The control group will receive the current standard of care.   The primary endpoint will be the myocardial infarct size as a percentage of at-risk myocardium at four days (±2 days), as measured by cardiac MRI.  Secondary safety and efficacy endpoints will also be evaluated.

The RAPID MI-ICE study enrolled 20 STEMI patients who were randomised to receive immediate percutaneous coronary intervention, with or without adjunct rapid endovascular cooling.   The study demonstrated that the induction of mild hypothermia (‹35oC) in STEMI patients prior to performing an angioplasty can save up to 38 percent more heart tissue than the current standard of care.  The conclusion that the rapid induction of hypothermia with endovascular catheter is safe and feasible in patients with acute MI prompted the initiation of the CHILL-MI study to investigate this technology in a larger multi-centre trial.

The Philips InnerCool RTx endovascular cooling system quickly and effectively cools patients from the inside out, even those with high body mass index (>30kg/m2) who often are considered “difficult-to-cool”.   A unique catheter with an integrated temperature sensor is placed below the heart via the femoral vein.  Once in place, the closed-loop system modulates whole body temperature without fluid introduction or exchange by circulating cool saline in the catheter.   This technology offers the fastest cooling rates of any temperature modulation therapy approach.  

“One of our goals with endovascular cooling is to offer a new treatment option for patients with STEMI,” said Derek Smith, Senior Vice President Therapeutic Care, Philips Healthcare.  “This novel therapy leverages Philips’ strong presence and capabilities in both the emergency department and cath lab.   Endovascular cooling is one of our growth initiatives and illustrates our strategy to offer new therapies in high-potential markets with the goal of improving the quality of life for patients.” 

For further information

Please contact:

Barbara Neate
Philips Electronics, Corporate Communications UK
Tel: +44 1483 293 071


About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity.” Headquartered in the Netherlands, Philips employs approximately 122,000 employees with sales and services in more than 100 countries worldwide. With sales of EUR 22.6 billion in 2011, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at


Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.